Alto Neuroscience (ANRO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$27.6M

Net income growth (year over year)

−56.09%

Net margin

—

Return on equity

−49.17%

EPS (trailing twelve months)

−$2.32

Book value per share

$6.25

P/E (trailing twelve months)

—

Price to book

3.97

Debt to assets

13.70%

Payout ratio

—

Dividend yield

—

Company profile

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

• How do I buy stock in Alto Neuroscience (ANRO)?

  ANRO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.